We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Pantec Biosolutions Unveils Preclinical Data for Transdermal Drug Delivery Platform
Product News

Pantec Biosolutions Unveils Preclinical Data for Transdermal Drug Delivery Platform

Pantec Biosolutions Unveils Preclinical Data for Transdermal Drug Delivery Platform
Product News

Pantec Biosolutions Unveils Preclinical Data for Transdermal Drug Delivery Platform

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Pantec Biosolutions Unveils Preclinical Data for Transdermal Drug Delivery Platform"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pantec Biosolutions AG reports promising preclinical in vitro data in support of the company’s novel P.L.E.A.S.E.® intraepidermal drug delivery platform.

Pantec Biosolutions has achieved further important milestones in the replacement of injection-based therapies with painless needle-free transdermal systems. In vitro permeation “proof-of-principle” studies with a series of small and large molecular weight therapeutics, demonstrate that P.L.E.A.S.E.® (Painless Laser Epidermal System) significantly increases drug transport of poorly and non-permeating therapeutic agents.

“Proof-of-principle”, according to Dr. Yogeshvar Kalia, (School of Pharmaceutical Sciences, University of Geneva and Scientific Advisor to Pantec Biosolutions), “means cumulative drug permeation that is at least equivalent to delivery from the existing dosage form, e.g., by subcutaneous injection.”

The company has completed in vitro permeation studies with several key hormones in its primary focus area of In Vitro Fertilization (IVF). The results formed the basis of collaboration agreements with a pharmaceuticals company and a patch development and manufacturing company.

Development of transdermal patch systems, optimized for use with the P.L.E.A.S.E.® technology, is underway with clinical results expected in 2009. At present, Pantec Biosolutions is financing the entire project and, in line with its business strategy, is open to licensing both its P.L.E.A.S.E.®  technology and the transdermal patches in a “one stop shop” concept.

In the area of pain management, Pantec Biosolutions has completed investigations with diclofenac (a nonsteroidal anti-inflammatory) and lidocaine (a topical anaesthetic).

The diclofenac results indicate that significantly more drug can be administered topically using P.L.E.A.S.E.® ; providing real scope for increasing the current range of indications. Furthermore, topical administration will alleviate the risk of gastrointestinal and other systemic side effects.

Lidocaine is a topical anaesthetic used to numb the skin and underlying tissue before needle-stick procedures, e.g. venipuncture, and at present the slow onset of effect limits its wider use. Microporation prior to lidocaine application results in substantially faster action and enables the needle procedure to be performed minutes after applying the anaesthetic.

Pantec Biosolutions also reports initial in vitro results with a large protein, showing significant delivery, in the double digit mg range, within 24 hours.

Dr. Christof Boehler, Pantec Biosolutions’ CEO, said: “We are very pleased to present such proof-of-principle data in the field of IVF, our lead therapeutic area, to our partners and investors. The IVF results together with the data in other therapeutic areas represent a further important milestone on our way to building partnerships with pharmaceutical and biotechnology companies”.